Scholarlink

Background <p>No multicenter study has validated cochlear dose constraints for hearing preservation in pediatric brain tumor patients in a real-world setting. Although the PENTEC review proposed a 35&#xa0;Gy mean cochlear dose threshold, supporting evidence from heterogeneous, multicenter pediatric cohorts remains scarce.</p> Purpose <p>To evaluate dosimetric, therapeutic, and clinical risk factors for sensorineural hearing loss (SNHL) after pediatric cranial radiotherapy in a national multicenter cohort, with a specific focus on validating the clinical relevance of the 35&#xa0;Gy mean cochlear dose threshold.</p> Methods <p>We retrospectively analyzed 88 children treated with cranial radiotherapy between 2014 and 2024 across four French pediatric radiotherapy centers participating in the national PediaRT registry. All patients had baseline and at least two post-radiotherapy audiograms graded according to the Chang Ototoxicity Scale, with SNHL defined as Chang grade ≥ 1a. Mean (Dmean) and minimum (Dmin) cochlear doses were extracted and analyzed using Kaplan–Meier estimates and Cox proportional hazards models.</p> Results <p>Over a median follow-up of 37&#xa0;months, 17 patients (19.3%) developed SNHL. In multivariate analysis, both a mean cochlear dose ≥ 35&#xa0;Gy (HR = 3.90; 95% CI: 1.24–12.23; p = 0.020) and cisplatin exposure (HR = 3.85; 95% CI: 1.40–10.64; p = 0.009) were independently associated with SNHL. The 5-year cumulative incidence of SNHL was 43.4% for Dmean ≥ 35&#xa0;Gy versus 13.1% for &lt; 35&#xa0;Gy (p = 0.0014), and 51.6% with cisplatin versus 12.4% without (p &lt; 0.001). A significant monotonic relationship between cochlear dose and SNHL severity was observed (p = 0.0011).</p> Conclusion <p>This study provides the first national, multicenter validation of the 35&#xa0;Gy mean cochlear dose threshold in a real-world pediatric population and identifies cisplatin exposure as a major independent risk factor. These findings support strict cochlear dose minimization during treatment planning and systematic long-term audiological surveillance in pediatric cancer survivorship care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sensorineural hearing loss after pediatric cranial radiotherapy: a multicenter analysis of dosimetric and clinical risk factors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月8日

查看全文
  • William Gehin,
  • Luc Ollivier,
  • Emmanuel Jouglar,
  • Claire Dossun,
  • Maria Jolnerovski,
  • Valérie Bernier-Chastagner

摘要

Background

No multicenter study has validated cochlear dose constraints for hearing preservation in pediatric brain tumor patients in a real-world setting. Although the PENTEC review proposed a 35 Gy mean cochlear dose threshold, supporting evidence from heterogeneous, multicenter pediatric cohorts remains scarce.

Purpose

To evaluate dosimetric, therapeutic, and clinical risk factors for sensorineural hearing loss (SNHL) after pediatric cranial radiotherapy in a national multicenter cohort, with a specific focus on validating the clinical relevance of the 35 Gy mean cochlear dose threshold.

Methods

We retrospectively analyzed 88 children treated with cranial radiotherapy between 2014 and 2024 across four French pediatric radiotherapy centers participating in the national PediaRT registry. All patients had baseline and at least two post-radiotherapy audiograms graded according to the Chang Ototoxicity Scale, with SNHL defined as Chang grade ≥ 1a. Mean (Dmean) and minimum (Dmin) cochlear doses were extracted and analyzed using Kaplan–Meier estimates and Cox proportional hazards models.

Results

Over a median follow-up of 37 months, 17 patients (19.3%) developed SNHL. In multivariate analysis, both a mean cochlear dose ≥ 35 Gy (HR = 3.90; 95% CI: 1.24–12.23; p = 0.020) and cisplatin exposure (HR = 3.85; 95% CI: 1.40–10.64; p = 0.009) were independently associated with SNHL. The 5-year cumulative incidence of SNHL was 43.4% for Dmean ≥ 35 Gy versus 13.1% for < 35 Gy (p = 0.0014), and 51.6% with cisplatin versus 12.4% without (p < 0.001). A significant monotonic relationship between cochlear dose and SNHL severity was observed (p = 0.0011).

Conclusion

This study provides the first national, multicenter validation of the 35 Gy mean cochlear dose threshold in a real-world pediatric population and identifies cisplatin exposure as a major independent risk factor. These findings support strict cochlear dose minimization during treatment planning and systematic long-term audiological surveillance in pediatric cancer survivorship care.